Last reviewed · How we verify

Antihistamine Cetirizine Hydrochloride — Competitive Intelligence Brief

Antihistamine Cetirizine Hydrochloride (Antihistamine Cetirizine Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (second-generation antihistamine). Area: Immunology / Allergy.

marketed H1-receptor antagonist (second-generation antihistamine) H1 histamine receptor Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Antihistamine Cetirizine Hydrochloride (Antihistamine Cetirizine Hydrochloride) — Goldman, Butterwick, Fitzpatrick and Groff. Cetirizine hydrochloride blocks histamine H1 receptors on cells, preventing histamine-mediated allergic responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antihistamine Cetirizine Hydrochloride TARGET Antihistamine Cetirizine Hydrochloride Goldman, Butterwick, Fitzpatrick and Groff marketed H1-receptor antagonist (second-generation antihistamine) H1 histamine receptor
montelukast and cetirizine montelukast and cetirizine Medical University of Lodz marketed Leukotriene receptor antagonist and H1-receptor antagonist combination CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine)
Ciclesonide & Levocetirizine Ciclesonide & Levocetirizine Handok Inc. marketed Inhaled corticosteroid + selective H1-receptor antagonist combination Glucocorticoid receptor (ciclesonide); H1 histamine receptor (levocetirizine)
Morphine-Promethazine Morphine-Promethazine Tel-Aviv Sourasky Medical Center marketed Opioid analgesic combination Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Hydroxyzine HCL Hydroxyzine HCL National Cancer Institute (NCI) marketed First-generation H1 antihistamine H1 histamine receptor
Olopatadine Nasal Spray Olopatadine Nasal Spray ORA, Inc. marketed Selective H1-receptor antagonist / mast cell stabilizer H1 histamine receptor
olopatadine (OLO) olopatadine (OLO) University of Chicago marketed Selective H1-receptor antagonist / mast cell stabilizer H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (second-generation antihistamine) class)

  1. UCB Pharma · 5 drugs in this class
  2. Organon and Co · 3 drugs in this class
  3. Brian J Lipworth · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Goldman, Butterwick, Fitzpatrick and Groff · 1 drug in this class
  6. HK inno.N Corporation · 1 drug in this class
  7. AAADRS Clinical Research Center · 1 drug in this class
  8. University Hospital, Grenoble · 1 drug in this class
  9. Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antihistamine Cetirizine Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/antihistamine-cetirizine-hydrochloride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: